Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 15, Issue 7, Pages 869-880Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/14737159.2015.1045490
Keywords
approval; cancer; companion diagnostics; FDA; personalized medicine
Categories
Ask authors/readers for more resources
Companion diagnostics are essential for the safe and effective use of the corresponding therapeutic products. The US FDA has approved a number of companion diagnostics used to select cancer patients for treatment with contemporaneously approved novel therapeutics. The processes of co-development and co-approval of a therapeutic product and its companion diagnostic have been a learning experience that continues to evolve. Using several companion diagnostics as examples, this article describes the challenges associated with the scientific, clinical and regulatory hurdles faced by FDA and industry alike. Taken together, this discussion is intended to assist manufacturers toward a successful companion diagnostics development plan.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available